Home > Healthcare > Pharmaceuticals > Finished Drug Form > Transthyretin Amyloidosis Treatment Market

Transthyretin Amyloidosis Treatment Market Trends

Report ID: GMI8484
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Transthyretin Amyloidosis Treatment Market Trends

Advancements in diagnostic techniques has significantly contributed to the market growth. With the development of more sensitive imaging modalities such as cardiac MRI and nuclear scintigraphy, along with improved genetic testing methods, early and accurate diagnosis has become more achievable.
For instance, recent advancements in nuclear cardiac imaging with technetium pyrophosphate scan, the diagnosis of ATTR-CM is possible without cardiac biopsy. Therefore, more patients are being screened and diagnosed with ATTR-CM.
These advancements not only facilitate timely treatment initiation but also enable better patient management and monitoring. Additionally, the introduction of novel biomarkers and the ongoing research into new diagnostic technologies promise further improvements in the diagnosis and management of transthyretin amyloidosis, propelling the market growth, and in turn propelling the rare disease treatment market as well.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Transthyretin amyloidosis treatment industry was valued at USD 5.9 billion in 2023 and is poised to expand at 7.5% CAGR between 2024 and 2032 owing to the increasing prevalence of transthyretin amyloidosis, a rare genetic disorder, coupled with advancements in treatment options for rare diseases.

The ATTR-CM segment generated USD 4.7 billion in revenue in 2023 and is estimated to grow at a notable CAGR from 2024-2032 owing to the rising advancements in diagnostics techniques that aid in timely intervention.

North America accounted 37.6% revenue share of the transthyretin amyloidosis treatment industry in 2023 and is set to expand at a considerable growth rate through 2032 due to well-established healthcare infrastructure, and high awareness about rare diseases among healthcare professionals and patients.

Some of the top transthyretin amyloidosis treatment companies are Acrotech Biopharma, LLC, AstraZeneca PLC, Astellas Pharma Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Ionis Pharmaceuticals, Inc., Johnson & Johnson, Prothena Biosciences Limited, Pfizer Inc., SOM Innovation Biotech, S.L.